Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05029362 · ClinicalTrials.gov registry record · NA
SmokefreeSGM, A Text-based Smoking Cessation Intervention for Sexual and Gender Minority Groups
A NA study of Smoking Cessation, sponsored by The University of Texas Health Science Center, Houston.
- Completed
- Registry status
- NA
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT05029362: Completed NA study of Smoking Cessation, sponsored by The University of Texas Health Science Center, Houston.
NCT05029362 is a NA study of Smoking Cessation that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 18 participants, below the 475-participant average among 188 other Smoking Cessation trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05029362, a NA study of Smoking Cessation, has completed, sponsored by The University of Texas Health Science Center, Houston.
- COMPLETED
- Registry status
- NA
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to pretest the design of a text-based smoking cessation program tailored to sexual minority individuals.
Primary Outcome
The 10-item System Usability Scale (SUS) was used to assess the usability of the SmokefreeSGM text messaging program. Total score ranges from 0 to 100, with a higher score indicating greater acceptability and a score above 75 indicating that the program is perceived as acceptable.
Conditions Studied
Interventions
- BEHAVIORAL SmokefreeSGM
Study Locations (1)
Texas
- The University of Texas Health Science Center at Houston - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2022-01-05 |
| Est. Completion | 2022-10-05 |
| Phase | NA |
What the finished NCT05029362 record still lists
NCT05029362 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 475-participant average among 188 other Smoking Cessation trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Smoking Cessation appearing as the primary indexed condition, and to 1 intervention - of which SmokefreeSGM is the first listed.
NCT05029362 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT05029362 about?
NCT05029362 is a clinical study titled "SmokefreeSGM, A Text-based Smoking Cessation Intervention for Sexual and Gender Minority Groups". The purpose of this study is to pretest the design of a text-based smoking cessation program tailored to sexual minority individuals.
What is the current status of trial NCT05029362?
This trial is currently completed. It is a NA study. The enrollment target is 18 participants. The study started on 2022-01-05. Estimated completion is 2022-10-05.
What conditions does trial NCT05029362 study?
This clinical trial studies the following conditions: Smoking Cessation.
What interventions are being tested in trial NCT05029362?
The interventions under investigation include: SmokefreeSGM (BEHAVIORAL).
Who is sponsoring clinical trial NCT05029362?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05029362 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoking Cessation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05029362's enrollment target sits among peer trials
18 180th of 188 higher than 7 of 188 other Smoking Cessation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Smoking Cessation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Clinical Research Evaluating Smoking Cessation With E-Cigarettes and Nicotine Therapy
RECRUITING · NA
-
Scalable TELeheaLth Cancer CARe: The STELLAR Program to Treat Cancer Risk Behaviors
RECRUITING · NA
-
ACT Lung Health Intervention: Phase Two
RECRUITING · NA
-
Refer2Quit: Evaluating a Proactive, Tailored, Population Health Approach for Tobacco Treatment for Household Smokers Through a Pediatric Care Network
RECRUITING · NA
-
Baby Steps III: Testing a Clinician and Patient Intervention to Promote Smoking Cessation Among Pregnant Women
RECRUITING · NA
-
Urban and Reservation Implementation of All Nations Breath of Life
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI